Downloaded 1,203 times
Uploaded bySanjay Yadav
Physiological pharmacokinetic models
This document discusses physiological pharmacokinetic models, which describe drug movement and disposition in the body based on organ blood flow and organ spaces penetrated by the drug. It presents different types of models, including blood flow-limited models, models incorporating drug binding, and membrane-limited models. It discusses key concepts like mean residence time, mean absorption time, and mean dissolution time. Physiological pharmacokinetic models provide a more exact description of drug concentrations over time compared to non-physiological models.
More Related Content
Similar to Physiological pharmacokinetic models
Physiological pharmacokinetic models
- 1. Presented by: Group C Sanjaykr. Yadav* Deepankar Ghosh Natraj S. Adhikari
- 2. INTRODUCTION Physiological Pharmacokineticsmodels are mathematical models describing Drug movement and disposition in the body based on organ blood flow and organ spaces penetrated by the drug Models are elaborated on the basis of known anatomy and physiology of humans and other animals Incorporates physiological, anatomical and physiochemical data
- 3. MERITS Ideally providean exact description of the time course of drug concentration in any organ or tissue. Able to provide greater insight to drug distribution in the body. Parameters of these models corresponds to actual physiological and anatomical measures. Introduce the possibility of animal scale-up which would provide a rational basis for the correlation of drug data among animal species.
- 4. DEMERITS Greater requirementsfor in vitro or in vivo data Statistical evaluation of uncertainty and variability more challenging Model development and implementation requires appropriate expertise
- 5. ASSUMPTION Exchange ofdrug between capillary blood and interstitial water is considered to be very rapid. Cell membrane is considered to be very permeable to the drug. Capillary membrane does not offer any resistance to drug permeation. Constant ratio of drug concentration between organ and venous blood is quickly established.
- 6. TYPES OF MODEL Blood flow limited model Physiologic Pharmacokinetic Model with Binding Membrane limited model
- 7. BLOOD FLOW LIMITEDMODEL Drug movement and disposition in the body based on organ blood flow and the organ spaces penetrated by the drug. In its simplest form, a physiologic pharmacokinetic model considers the drug to be blood flow limited. Drugs are carried to organs by arterial blood and leave organs by venous blood. Differential mass balance equations are written for each compartment to describe the inflow, outflow, accumulation, and disappearance of drug, and are solved simultaneously with the aid of a computer.
- 8. Figure 1: Noneliminating tissue organ • Uptake of drug into the tissues is rapid, and a constant ratio of drug concentrations between the organ and the venous blood is quickly established. • This ratio is the tissue/blood partition coefficient: where P is the partition coefficient ……..1 • The magnitude of the partition coefficient can vary depending on the drug and on the type of tissue. • for example: Adipose tissue has a high partition for lipophilic drugs
- 9. The rateof blood flow to the tissue is expressed as Qt (mL/min), and the rate of change in the drug concentration with respect to time within a given tissue organ is expressed as ……..2 ……..3 where Cart is the arterial blood drug concentration and Cven is the venous blood drug concentration. Qt is blood flow and represents the volume of blood flowing through a typical tissue organ per unit of time
- 10. If druguptake occurs in the tissue, the incoming concentration, Cart, is higher than the outgoing venous concentration, Cven. In the blood flow-limited model, drug concentration in the blood leaving the tissue and the drug concentration within the tissue are in equilibrium, and Cven may be estimated from the tissue/blood partition coefficient Using equation 1 and 3; ……..4 • Equation 4 describes drug distribution in a non eliminating organ or tissue group. For example, drug distribution to muscle, adipose tissue, and skin is represented in a similar manner by Equations 5, 6, and 7, respectively
- 11. For tissueorgans in which drug is eliminated , parameters representing drug elimination from the liver (k LIV) and kidney (k KID) are added to account for drug removal through metabolism or excretion. Figure 2: A typical eliminating tissue organ
- 12. The rateof drug elimination may be described for each organ or tissue ……..5 ……..6 ……..7 ……..8 ……..9 ……..10 where LIV = liver, SP = spleen, GI = gastrointestinal tract, KID = kidney, LU = lung, FAT = adipose, SKIN = skin, and MUS = muscle
- 13. The massbalance for the rate of change in drug concentration in the blood pool is: ……..11
- 14. Figure 3: Exampleof blood flow to organs in a physiologic pharmacokinetic model
- 15. Figure 4: DrugDistribution throughout the body
- 16. PHYSIOLOGIC PHARMACOKINETIC MODEL WITHBINDING The physiologic pharmacokinetic model assumes flow- limited drug distribution without drug binding to either plasma or tissues. In reality, many drugs are bound to a variable extent in either plasma or tissues. With most physiologic models, drug binding is assumed to be linear (not saturable or concentration dependent). Bound and free drug in both tissue and plasma are in equilibrium. Further, the free drug in the plasma and in the tissue equilibrates rapidly.
- 17. Free drugconcentration in the tissue and the free drug concentration in the emerging blood are equal: ……..12 ……..13 ……..14 where fb is the blood free drug fraction, ft is the tissue free drug fraction, Ct is the total drug concentration in tissue, and C b is the total drug concentration in blood. Partition ratio, P t, of the tissue drug concentration to that of the plasma drug concentration is: ……..15
- 18. By assuminglinear drug binding and rapid drug equilibration, the free drug fraction in tissue and blood may be incorporated into the partition ratio and the differential equations. These equations are similar to those above except that free drug concentrations are substituted for Cb. Drug clearance in the liver is assumed to occur only with the free drug. The inherent capacity for drug metabolism (and elimination) is described by the term Clint.
- 19. General massbalance of various tissues is described by Equation 16 or ……..16 For liver metabolism ……..17
- 20. Mass balancefor the drug in the blood pool is: ……..18 • The influence of binding on drug distribution is an important factor in interspecies differences in pharmacokinetics. • Animal data may predict drug distribution in humans by taking into account the differences in drug binding.
- 21. BLOOD FLOW-LIMITED VERSUS DIFFUSION-LIMITEDMODEL BLOOD FLOW LIMITED MODEL DIFFUSION-LIMITED MODEL Rapid drug equilibrium assumes that drug diffusion is extremely fast and that the cell membrane offers no barrier to drug permeation cell membrane acts as a barrier for the drug, which gradually permeates by diffusion If no drug binding is involved, the tissue drug concentration is the same as that of the venous blood leaving the tissue blood flow is very rapid and drug permeation is slow, a drug concentration gradient is established between the tissue and the venous blood Rate limiting step is Blood flow Rate limiting step is Permeation across the cell membrane assumption greatly simplifies the mathematics involved time lag in equilibration between blood and tissue, the pharmacokinetic equation for the diffusion-limited model is very complicated.
- 22. EXAMPLES OF DRUGDESCRIBED BY PHYSIOLOGIC PHARMACOKINETIC MODEL Drug Category Comment Thiopental Anaesthetic Blood flow Limited Nicotine Stimulant Blood flow Limited Lidocaine Antiarrhythmic Blood flow Limited Methotrexate Antineoplastic Plasma flow Limited Biperiden Anticholinergic Blood flow Limited Cisplatin Antineoplastic Plasma, Multiple Metabolite , Binding
- 23. MEAN RESIDENCE TIME(MRT) Describes the average time for all the drug molecules to reside in the body. Also considered as the mean transit time or mean sojourn time. The residence time for the drug molecules in the dose may be sorted into groups i (i = 1, 2, 3, . . . , m) according to their residing time. The total residence time is the summation of the number of molecules in each group i multiplied by the residence time, ti, for each group. The summation of n i (number of molecules in each group) is the total number of molecules, n. MRT is the total residence time for all molecules in the body divided by the total number of molecules in the body, as shown in equation 19.
- 24. where ni isthe number of molecules and ti is the residence time of the ith group of molecules where Dei (i = 1, 2, 3, . . . , m) is the amount of drug (mg) in the ith group with residence time ti.
- 25. For IV BOLUS ……..22 ……..21 where AUMCis the area under the (first) moment-versus-time curve from t = 0 to infinity. AUC is the area under plasma time-versus-concentration curve from t = 0 to infinity.
- 26. MRT FOR MULTICOMPARTMENT MODEL with Elimination from the Central Compartment For Central compartment For Peripheral compartment ……..23 ……..24
- 27. MRT ismerely the expected value or mean of the distribution. MRT provides a fundamentally different approach than classical pharmacokinetic models, which involve the concept of dose, half-life, volume, and concentration. MRT is an alternative concept to describe how drug molecules move in and out of a system. The concept is well established in chemical kinetics, where the relationships between MRT and rate constants for different systems are known. In the last two decades, MRT has been well characterized for various pharmacokinetic models, although MRT application is less developed in pharmacodynamics.
- 28. STATISTICAL MOMENT THEORY Statistical moment theory provides a unique way to study time- related changes in macroscopic events. A macroscopic event is considered as the overall event brought about by the constitutive elements involved. For example, in chemical processing, a dose of tracer molecules may be injected into a reactor tank to track the transit time (residence time) of materials that stay in the tank. The constitutive elements in this example are the tracer molecules, and the macroscopic events are the residence times shared by groups of tracer molecules. Each tracer molecule is well mixed and distributes non- interactively and randomly in the tank
- 29. A probabilitydensity function f(t) multiplied by t m and integrated over time yields the moment curve (Equation 23). The moment curve shows the characteristics of the distribution. where f(t) is the probability density function, t is time, and m is the mth moment ……..25 For example, when m = 0, substituting for m = 0 yields Equation 24 called the zero moment( ), ……..26 If the distribution is a true probability function, the area under the zero moment curve is 1.
- 30. Substituting intoEquation 23 with m = 1, Equation 25 gives the first moment , The area under the curve f(t) times t is called the AUMC, or the area under the first moment curve. The first moment, defines the mean of the distribution. Similarly, when m = 2, Equation 23 becomes the second moment, : Where defines the variance of the distribution. Higher moments, such as 3 or 4, represent skewness and kurtosis of the distribution. Equation 23 is therefore useful in characterizing family of moment curves of a distribution. The principal use of the moment curve is the calculation of the MRT of a drug in the body. The elements of the distribution curve describe the distribution of drug molecules after administration and the residence time of the drug molecules in the body. ……..27 ……..28
- 31. Example Question: An antibiotic wasgiven to two subjects by an IV bolus dose of 1000 mg. The drug has a volume of distribution of 10 L and follows a one-compartment model with an elimination constant of (1) 0.1 hr– 1 and (2) 0.2 hr– 1 in the two subjects. Determine the MRT from each C p–time curve and compare your values with the MRT determined by taking the reciprocal of k. Solution Non compartmental Approach (MRT = AUMC/AUC) 1. Multiply each time point with the corresponding plasma C p to obtain points for the moment curve. Use the trapezoid rule and sum the area to obtain area under the moment curve (AUMC1) for subject 1. Also, determine the area under the plasma curve using the trapezoid rule. 2. The steps are as follows. a. Multiply each C p by t as in column 5 b. Sum all C p x t values, and find the area under the moment curve (AUMC)—that is, 9986.45 (g/mL) hr2 c. Estimate tail area of the moment curve (beyond the last data point) using the equation ……..29
- 32. Substituting thelast data point, C p = 0.00454 g/mL, the last time point, 100 hours, and the last moment curve point, 0.454 (g/mL) hr2: d. Estimate AUC using the trapezoid rule from columns 1 and 2 (AUC = 1000.79 g/mL/hr).
- 34. MEAN ABSORPTION TIME(MAT) AND MEAN DISSOLUTION TIME (MDT) After IV bolus injection, the rate of systemic drug absorption is zero, because the drug is placed directly into the bloodstream. The MRT calculated for a drug after IV bolus injection basically reflects the elimination rate processes in the body. After oral drug administration, the MRT is the result of both drug absorption and elimination. The relationship between the mean absorption time, MAT, and MRT is given by ……..30
- 35. For aone-compartment model, MRTIV = 1/k In some cases, IV data are not available and an MRT for a solution may be calculated. The mean dissolution time (MDT), or in-vivo mean dissolution time, for a solid drug product is MDT reflects the time for the drug to dissolve in vivo. MDT is most readily estimated for the drugs that follow the kinetics of a one-compartment model. MDT is considered model independent because MRT is model independent. MDT has been used to compare the in-vitro dissolution versus in-vivo bioavailability for immediate-release and extended-release drug products. ……..31 ……..32
- 36. Example Data foribuprofen are shown in table 2 and 3 Serum concentrations for ibuprofen after a capsule and a solution are tabulated as a function of time
- 37. For Capsule For solution The MRT was determined using the trapezoid method and Equation 23 The MRT for the solution was 2.63 hours and for the product was 4.48 hours. Therefore, MDT for the product is 4.48 – 2.63 = 1.85 hours
- 38. Applying Equation 22.52directly Alternatively, MDT obtained for the product differs according to the method of calculation. Errors in calculating the elimination constant, k, may greatly affect the values for MAT and MDT. Equation 32 is recommended because it is less affected by k.
- 39. REFERENCE 1. Gibaldi M,Perrier D. (2007). Pharmacokinetics (2nd ed., Vol. 15). New York: Informa healthcare.355-80 2. Shargel L, Wu-pong S. et al (2004). Applied Biopharmaceutics and pharmacokinetics (5th ed.). New York: McGraw-Hill Medical.